Ikena Oncology, Inc. (IKNA) — Financial statements
Income statement, balance sheet, and cash flow for Ikena Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 9↓41.3% | 16↓49.6% | 31 | |
| Cost of Revenue | 0.00↓100.0% | 0.49↓52.0% | 1↓98.4% | 64↑36.5% | 47 | |
| Gross Profit | 0.00↑100.0% | -0.49↓106.0% | 8↓40.1% | 14↑184.3% | -16 | |
| Operating Expenses | ||||||
| R&D Expenses | 29↓6.1% | 30↓49.1% | 60↓7.3% | 64↑36.5% | 47 | |
| General & Administrative Expenses | 21↓12.5% | 24↓5.0% | 25↑12.3% | 22↑23.2% | 18 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 21↓12.5% | 24↓5.0% | 25↑12.3% | 22↑23.2% | 18 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -1↑49.9% | -2↑95.7% | -47 | |
| Operating Expenses | 49↓8.9% | 54↓35.3% | 84↓1.1% | 84↑369.0% | 18 | |
| Total Costs & Expenses | 0.00↓100.0% | 55↓35.5% | 85↓2.2% | 87↑32.9% | 65 | |
| Operating Results | ||||||
| Operating Income | -48↑11.2% | -55↑27.7% | -75↓6.4% | -71↓107.7% | -34 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.49↓52.0% | 1↑35.8% | 0.75↑38.1% | 0.54 | |
| EBITDA | -48↑0.3% | -49↑34.7% | -74↓6.0% | -70↓108.8% | -34 | |
| EBIT | 0.00↑100.0% | -49↑34.9% | -75↓6.4% | -71↓107.7% | -34 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 7↑3.7% | 7↑230.9% | 2↑9243.5% | 0.02 | |
| Interest Income | 0.00↓100.0% | 7↑3.7% | 7↑230.9% | 2↑9243.5% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -5 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 3↓49.7% | 5↓22.8% | 7↑231.4% | 2↑9200.0% | 0.02 | |
| Income Before Tax | -46↑6.9% | -49↑28.2% | -68↑0.6% | -69↓101.6% | -34 | |
| Income Tax Expense | 0.35↑130.3% | 0.15↑193.8% | -0.16 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 0.00↑100.0% | -49↑27.8% | -68↑0.9% | -69↓101.6% | -34 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -52↓6.4% | -49↑27.8% | -68↑0.9% | -69↓101.6% | -34 | |
| Bottom-Line Net Income | 0.00↑100.0% | -49↑27.8% | -68↑0.9% | -69↓101.6% | -34 | |
| EPS (Basic) | 0.00↑100.0% | -1.02↑37.4% | -1.63↑14.2% | -1.90↓100.0% | -0.95 | |
| EPS (Diluted) | 0.00↑100.0% | -1.02↑37.4% | -1.63↑14.2% | -1.90↓100.0% | -0.95 | |
| Weighted Average Shares | 0.00↓100.0% | 48↑15.6% | 42↑15.3% | 36↑0.6% | 36 | |
| Weighted Average Diluted Shares | 0.00↓100.0% | 48↑15.6% | 42↑15.3% | 36↑0.6% | 36 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.